Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.
暂无分享,去创建一个
[1] S. Kato,et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer , 2013, International Journal of Clinical Oncology.
[2] P. Tappenden,et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisa , 2013, Health technology assessment.
[3] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[4] T. Yamanaka,et al. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. , 2012, Japanese journal of clinical oncology.
[5] M. Parmar,et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. , 2012, Cancer treatment reviews.
[6] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Tae Won Kim,et al. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status , 2012, Investigational New Drugs.
[8] R. Bianco,et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer , 2012, British Journal of Cancer.
[9] E. Maccaroni,et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Meyerhardt,et al. Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer , 2012, PloS one.
[11] J. Pagès,et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] T. Price,et al. Cetuximab in metastatic colorectal cancer , 2012, Expert review of anticancer therapy.
[13] A. Mahmoud,et al. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC) , 2012, Journal of Cancer Research and Clinical Oncology.
[14] M. Fakih,et al. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. , 2012, Clinical colorectal cancer.
[15] J. Sakamoto,et al. Phase II multicenter study of second-line FOLFIRI plus cetuximab (FLIER) in patients with KRAS wild-type metastatic colorectal cancer: Final analysis of survival and additional analysis of BRAF, PI3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Matsuo,et al. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. , 2011, European journal of cancer.
[17] Shung-Haur Yang,et al. The status of EGFR‐associated genes could predict the outcome and tumor response of chemo‐refractory metastatic colorectal patients using cetuximab and chemotherapy , 2011, Journal of surgical oncology.
[18] M. Hou,et al. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens. , 2011, Genetics and molecular research : GMR.
[19] S. Curley,et al. Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified? , 2011, Cancer.
[20] M. Yasukawa,et al. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.
[21] E. Vasile,et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. , 2011, Critical reviews in oncology/hematology.
[22] K. Vistisen,et al. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer , 2011, Acta oncologica.
[23] R. Lim,et al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. , 2011, World journal of gastroenterology.
[24] J. Lindebjerg,et al. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer , 2011, BMC Cancer.
[25] S. Barni,et al. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis , 2011, International Journal of Colorectal Disease.
[26] S. Kato,et al. Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive advanced and/or metastatic colorectal cancer: Evaluation of the efficacy and safety based on KRAS mutation status (T- CORE0801). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Peeters,et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab , 2010, International Journal of Colorectal Disease.
[28] Yu-hong Li,et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. , 2010, World Journal of Gastroenterology.
[29] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[31] S. Jang,et al. A phase II trial of cetuximab/irinotecan every 2 weeks in patients with metastatic colorectal cancer (CRC) that expresses wild-type KRAS after failure to first-line therapy with an irinotecan-containing regimen with or without detectable epidermal growth factor receptor (EGFR) expression. , 2010 .
[32] I. Sperduti,et al. FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy. , 2010 .
[33] I. Christensen,et al. Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. , 2010 .
[34] E. Van Cutsem,et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] J. Reid,et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[37] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[38] J. Kim,et al. The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients , 2009, Oncology.
[39] N. Funel,et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] C. Tournigand,et al. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] N. Pavlakis,et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[44] W. Scheithauer,et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Gonen,et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[49] F. Recchia,et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX , 2004, British Journal of Cancer.
[50] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[51] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.